4//SEC Filing
Cormorant Private Healthcare Fund III LP 4
Accession 0001567619-20-020222
CIK 0001750284other
Filed
Nov 22, 7:00 PM ET
Accepted
Nov 23, 4:59 PM ET
Size
20.4 KB
Accession
0001567619-20-020222
Insider Transaction Report
Form 4
Cormorant Asset Management, LLC
10% Owner
Transactions
- Conversion
Series B Convertible Preferred Stock
2020-11-23−2,122,367→ 0 total(indirect: See Footnotes)→ Common Stock (2,122,367 underlying) - Conversion
Series C Convertible Preferred Stock
2020-11-23−723,177→ 0 total(indirect: See Footnotes)→ Common Stock (723,177 underlying) - Purchase
Common Stock
2020-11-23$19.00/sh+425,000$8,075,000→ 3,270,544 total(indirect: See Footnotes) - Conversion
Common Stock
2020-11-23+2,845,544→ 2,845,544 total(indirect: See Footnotes)
Footnotes (6)
- [F1]Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.
- [F2]Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
- [F3]Represents (i) 538,464 shares of Common Stock held by the Master Fund, (ii) 1,684,920 shares of Common Stock held by Fund II, (iii) 587,871 shares of Common Stock held by Fund III, and (iv) 34,289 shares of Common Stock held by the Account.
- [F4]Shares reported herein as purchased on November 23, 2020 represent (i) 404,940 shares purchased by the Master Fund, and (ii) 20,060 shares purchased by the Account.
- [F5]The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 412,342 shares held by the Master Fund, (ii) 1,684,920 shares held by Fund II, and (iii) 25,105 shares held by the Account.
- [F6]The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 126,122 shares held by the Master Fund, (ii) 587,871 shares held by Fund III, and (iii) 9,184 shares held by the Account.
Documents
Issuer
Olema Pharmaceuticals, Inc.
CIK 0001750284
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001817320
Filing Metadata
- Form type
- 4
- Filed
- Nov 22, 7:00 PM ET
- Accepted
- Nov 23, 4:59 PM ET
- Size
- 20.4 KB